AbbVie, Alloy Therapeutics Ink Deal to Develop Next-Gen Antibody Platform.
Share this article
Corporate
Score 65
Bullish
AbbVie, Alloy Therapeutics Ink Deal to Develop Next-Gen Antibody Platform
Mar 20, 2026 04:29 UTC
ABBV, ALLO, XLV
Medium term
Related Articles
Score 85
Bearish
Elon Musk misled Twitter investors ahead of $44 billion acquisition, jury says
Mar 20, 23:29
Score 65
Netflix Expands Live Event Strategy with BTS Comeback Spectacular
Mar 20, 23:00
Score 72
Bullish
Nuclear Energy Firm X-Energy Files for US IPO Despite War
Mar 20, 22:53
Score 35
Activist Investor Jonathan Litt Withdraws Board Bid for First Industrial REIT
Mar 20, 21:48
Stay Ahead of the Markets
Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.